Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04183192 · ClinicalTrials.gov registry record · Phase 1
Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists
A Phase 1 study, sponsored by Food and Drug Administration (FDA).
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT04183192 is a Phase 1 study that has completed, run by Food and Drug Administration (FDA). The registered enrollment target is 72 participants.
The verdict
NCT04183192, a Phase 1 study, has completed, sponsored by Food and Drug Administration (FDA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study is designed to assess pharmacokinetics and pharmacodynamics of mepolizumab and reslizumab across an appropriate dose range to inform clinical trial operating characteristics for future clinical pharmacology pharmacodynamics similarity studies. This is a randomized, placebo-controlled, single-dose, parallel arm study in 72 healthy subjects assigned to one of four dose groups (low, intermediate low, intermediate high, and high) of each drug (mepolizumab or reslizumab) or placebo.
Interventions
- BIOLOGICAL Mepolizumab
- BIOLOGICAL Reslizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2020-02-17 |
| Est. Completion | 2021-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04183192
The ClinicalTrials.gov registry entry for NCT04183192 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Food and Drug Administration (FDA), which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mepolizumab is the first listed.
NCT04183192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04183192 about?
NCT04183192 is a clinical study titled "Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists". This study is designed to assess pharmacokinetics and pharmacodynamics of mepolizumab and reslizumab across an appropriate dose range to inform clinical trial operating characteristics for future clinical pharmacology pharmacodynamics similarity studies. This is a randomized, placebo-controlled, si...
What is the current status of trial NCT04183192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2020-02-17. Estimated completion is 2021-04-04.
What interventions are being tested in trial NCT04183192?
The interventions under investigation include: Mepolizumab (BIOLOGICAL), Reslizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04183192?
This trial is sponsored by Food and Drug Administration (FDA), which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.